Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report

Luo,Yawen; Lin,Lin; Shufeng,Chen; Liu,Chun; Li,Zhuanghua; Liu,Kejun

doi:10.3892/ol.2024.14634

Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report

Authors:
- Yawen Luo
- Lin Lin
- Chen Shufeng
- Chun Liu
- Zhuanghua Li
- Kejun Liu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Shenzhen University, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518035, P.R. China, Department of Internal Medicine‑Oncology, Dongguan Wangniudun Hospital, Dongguan, Guangdong 518131, P.R. China, Dongguan Institute of Clinical Cancer Research, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital of Southern Medical University, Dongguan People's Hospital, Dongguan, Guangdong 518131, P.R. China
Published online on: August 16, 2024 https://doi.org/10.3892/ol.2024.14634
Article Number: 501
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epidermal growth factor receptor (EGFR) mutations have emerged as the most well‑studied oncogenic alterations in advanced non‑small cell lung cancer. The presence of single common or rare EGFR mutations and extra complex EGFR mutations correlates with the response sensitivity to EGFR tyrosine kinase inhibitors. Therefore, given the lack of evidence for the emergence of rare EGFR mutation types, the pathogenic mechanisms of uncommon EGFR mutations and the optimal treatment strategies remain to be explored further. The present study describes the case of a patient diagnosed with lung adenocarcinoma (LUAD) carrying two rare EGFR exon 18 indel/G719C and exon 19 L747S mutations, in which persistent lesion shrinkage was exhibited within 16 months of osimertinib treatment. Given the paucity of clinical trials for the treatment of LUAD harboring complex EGER mutations, the present detailed case description may provide clinicians with effective clinical experience in treating patients.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Dong J, Li B, Lin D, Zhou Q and Huang D: Advances in targeted therapy and immunotherapy for non-small cell lung cancer based on accurate molecular typing. Front Pharmacol. 10:2302019. View Article : Google Scholar : PubMed/NCBI
3	Bi X, Song P, Wang C, Zhang X and Liu C: Genomic profiling reveals non-small cell lung cancer with common mutations of EGFR exon 20 and exon 21: A case report. Transl Cancer Res. 11:1423–1428. 2022. View Article : Google Scholar : PubMed/NCBI
4	Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162. 2014. View Article : Google Scholar : PubMed/NCBI
5	Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY and Yang PC: Effectiveness of tyrosine kinase inhibitors on ‘uncommon’ epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 17:3812–3821. 2011. View Article : Google Scholar : PubMed/NCBI
6	Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, et al: American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 27:6251–6266. 2009. View Article : Google Scholar : PubMed/NCBI
7	Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, et al: Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: A multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 25:126–131. 2014. View Article : Google Scholar : PubMed/NCBI
8	Won YW, Han JY, Lee G, Park SY, Lim KY, Yoon KA, Yun T, Kim HT and Lee JS: Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations. J Clin Pathol. 64:947–952. 2011. View Article : Google Scholar : PubMed/NCBI
9	Qin BD, Jiao XD, Yuan LY, Liu K, Wang Z, Qin WX and Zang YS: The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): A case report and literature review. Onco Targets Ther. 10:4739–4745. 2018. View Article : Google Scholar : PubMed/NCBI
10	Li K, Yang M, Liang N and Li S: Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution (Review). Oncol Rep. 37:1347–1358. 2017. View Article : Google Scholar : PubMed/NCBI
11	Zhang T, Wan B, Zhao Y, Li C, Liu H, Lv T, Zhan P and Song Y: Treatment of uncommon EGFR mutations in non-small cell lung cancer: New evidence and treatment. Transl Lung Cancer Res. 8:302–316. 2019. View Article : Google Scholar : PubMed/NCBI
12	Chang YS, Tu SJ, Chen YC, Liu TY, Lee YT, Yen JC, Fang HY and Chang JG: Mutation profile of non-small cell lung cancer revealed by next generation sequencing. Respir Res. 22:32021. View Article : Google Scholar : PubMed/NCBI
13	Goel S, Bergholz JS and Zhao JJ: Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 22:356–372. 2022. View Article : Google Scholar : PubMed/NCBI
14	Gong W, Wang L, Zheng Z, Chen W, Du P and Zhao H: Cyclin-dependent kinase 6 (CDK6) is a candidate diagnostic biomarker for early non-small cell lung cancer. Transl Cancer Res. 9:95–103. 2020. View Article : Google Scholar : PubMed/NCBI
15	Chen X, Wu Y, Wang X, Xu C, Wang L, Jian J, Wu D and Wu G: CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration-resistant prostate cancer. Eur J Med Res. 27:1052022. View Article : Google Scholar : PubMed/NCBI
16	Sitthideatphaiboon P, Teerapakpinyo C, Korphaisarn K, Leelayuwatanakul N, Pornpatrananrak N, Poungvarin N, Chantranuwat P, Shuangshoti S, Aporntewan C, Chintanapakdee W, et al: Co-occurrence CDK4/6 amplification serves as biomarkers of de novo EGFR TKI resistance in sensitizing EGFR mutation non-small cell lung cancer. Sci Rep. 12:21672022. View Article : Google Scholar : PubMed/NCBI
17	Børresen AL, Andersen TI, Eyfjörd JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S, et al: TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer. 14:71–75. 1995. View Article : Google Scholar : PubMed/NCBI
18	Gu J, Zhou Y, Huang L, Ou W, Wu J, Li S, Xu J, Feng J and Liu B: TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis. Mol Clin Oncol. 5:705–713. 2016. View Article : Google Scholar : PubMed/NCBI
19	González-Aguilera JJ, Oliart S, Azcoita MM and Fernández-Peralta AM: Simultaneous mutations in K-ras and TP53 are indicative of poor prognosis in sporadic colorectal cancer. Am J Clin Oncol. 27:39–45. 2004. View Article : Google Scholar : PubMed/NCBI
20	Canale M, Petracci E, Delmonte A, Bronte G, Chiadini E, Ludovini V, Dubini A, Papi M, Baglivo S, De Luigi N, et al: Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs. J Clin Med. 9:10472020. View Article : Google Scholar : PubMed/NCBI
21	Fang YF and Liu PC: Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report. Thorac Cancer. 12:3429–3432. 2021. View Article : Google Scholar : PubMed/NCBI
22	Shan CG, Wang H, Lin T, Liu D, Wen L, Chen ZJ, Zhen JJ, Lai MY, Zhang L, Zou X, et al: A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: A case report. Ann Palliat Med. 10:5897–5901. 2021. View Article : Google Scholar : PubMed/NCBI
23	Cho JH, Lim SH, An HJ, Kim KH, Park KU, Kang EJ, Choi YH, Ahn MS, Lee MH, Sun JM, et al: Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: A multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 38:488–495. 2020. View Article : Google Scholar : PubMed/NCBI
24	Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS and Costa DB: Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 8:45–51. 2013. View Article : Google Scholar : PubMed/NCBI
25	Grolleau E, Haddad V, Boissière L, Falchero L and Arpin D: Clinical efficacy of osimertinib in a patient presenting a double EGFR L747S and G719C mutation. J Thorac Oncol. 14:e151–e153. 2019. View Article : Google Scholar : PubMed/NCBI